The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer; Roche
Research Funding - AstraZeneca; Novartis; Roche
A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Dendreon; Genentech; GlaxoSmithKline; Janssen; Lilly; Merck
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck
 
Thomas Powles
No Relationships to Disclose
 
Shengting Li
Employment - Tasly Pharmaceuticals
Leadership - Tasly Pharmaceuticals
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Delphine Hennicken
Employment - Bristol-Myers Squibb
 
Guru Sonpavde
Honoraria - Onclive; Physicans' Education Resource; UpToDate
Consulting or Advisory Role - Agensys; Amgen; Argos Therapeutics; AstraZeneca; bioTheranostics; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Janssen; Merck; NCCN; Novartis; Pfizer; Sanofi
Speakers' Bureau - Clinical Care Options
Research Funding - Amgen/Onyx; Argos Therapeutics; Bayer; Boehringer Ingelheim; Celgene (Inst); Merck